| Literature DB >> 27278520 |
Hongdong Huang1,2, Yang Luo1, Yumei Liang2, Xidai Long3, Youming Peng4, Zhihua Liu1, Xiaojun Wen1, Meng Jia1, Ru Tian1, Chengli Bai1, Cui Li1, Fuliang He5,6, Qiushi Lin6, Xueyan Wang7, Xiaoqun Dong5,6.
Abstract
CD4(+)CD25(+) T cells are critical for maintenance of immunologic self-tolerance. We measured the number of CD4(+)CD25(+) cells in the patients with primary malignant hypertension related kidney injury, to explore the molecular pathogenesis of this disease. We selected 30 patients with primary malignant hypertension related kidney injury and 30 healthy volunteers. Information on clinical characteristics and laboratory tests was obtained from each subject. The number of CD4(+)CD25(+) cells and glomerular injury were assessed by flow cytometry and histopathology, respectively. Both serum IL-2, IL-4, and IL-6 and endothelial cell markers were analyzed by ELISA. ADAMTS13 antibody was detected by Western blotting. CD4(+)CD25(+) cells were significantly reduced in patients with primary malignant hypertension related kidney injury compared to controls (P < 0.05). The number of CD4(+)CD25(+) cells was negatively related to blood urea nitrogen, serum uric acid, proteinuria, and supernatant IL-4; whereas positively associated with estimated glomerular filtration rate in patients. Gradually decreasing CD4(+)CD25(+) cells were also found as increasing renal injury. Additionally, patients exhibited increasing supernatant IL-4, serum IL-2 and IL-6, endothelial cell markers, and anti-ADAMTS13 antibody compared with controls (all P < 0.05). CD4(+)CD25(+) cells may play a key role in the pathogenesis of primary malignant hypertension related kidney injury.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27278520 PMCID: PMC4899787 DOI: 10.1038/srep27659
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Live-dead lymphocytes in peripheral blood.
Lymphocytes were counted using the indicated gates R1 by flow cytometry. (B) Dead lymphocytes; I: patients with primary malignant hypertension related kidney injury; II: Controls. Live, Dead lymphocytes respectively were not significantly different in between patients and controls (all P > 0.05).
Figure 2CD4+CD25+ cells in peripheral blood.
CD4+CD25+ cells were counted using the indicated gates by flow cytometry. B4: CD4+CD25+cells; I: patients with primary malignant hypertension related kidney injury; II: Controls. CD4+CD25+ cells dramaticlly decreased in patients compared to controls (P < 0.05).
The number of CD4+CD25+ cells in peripheral blood (%, mean ± SD).
| Index | Patients | Controls |
|---|---|---|
| CD4+CD25+ cells | 0.85 ± 0.106a | 2.93 ± 0.207 |
aP < 0.05.
Clinical and histopathological findings in patients and controls.
| Index (mean ± SD) | Patients | Controls |
|---|---|---|
| BP (systolic/diastolic) | 187.5 ± 16.3*/140 ± 7.2* | 124 ± 11.5/73 ± 9.8 |
| Proteinuria (g/day) | 1.25 ± 0.31 | – |
| Hematuria (×104 cells/mL) | 364.75 ± 2.18 | – |
| BUN (mg/dL) | 28.7 ± 0.75* | 12.5 ± 0.13 |
| Serum Cr. (mg/dL) | 6.83 ± 0.25* | 0.58 ± 0.12 |
| Serum uric acid (μmol/L) | 467.62 ± 73.81* | 246.37 ± 28.34 |
| eGFR (mL/min/1.73 m2) | 67.12 ± 10.23* | 101.32 ± 7.41 |
| Serum C3 (mg/dL) | 119.5 ± 15.4 | 121.5 ± 13.7 |
| Serum IL-2 (pg/ml) | 104.6 ± 16.3* | 24.7 ± 15.2 |
| Supernatant IL-4 (pg/ml) | 536 ± 24.03* | 213.46 ± 35.67 |
| Serum IL-6 (pg/ml) | 60.21 ± 12.41* | 30.43 ± 11.42 |
| AI/CI (median) | 10.4 ± 2.1/3.6 ± 0.5 | – |
| vWF (%) | 215.73 ± 12.40 | – |
| VCAM (ng/mL) | 1135.26 ± 143.87 | – |
| AECA (positive %) | 72 | – |
| ADAMTS13-antibody (positive %) | 81 | – |
BP, Blood pressure; eGFR, estimated glomerular filtration rate; AI, activity index; CI, chronicity index; vWF, von Wille brand factor; VCAM, vascular cell adhesion molecule; AECA, anti -endothelial cell antibody.
*P < 0.05 compared to controls.
Figure 3Serum ADAMTS13 antibody by Western blotting.
ADAMTS13 antibody (positive %) accounted for 81% of the primary MHTN related kidney injury patients. Controls were negative. Lane M: Marker; lane 1: Controls; lane 2: Controls; lane 3: primary MHTN related kidney injury patients (Mild lesion); lane 4: primary MHTN related kidney injury patients (Moderate lesion); lane 5: primary MHTN related kidney injury patients(Marked lesion).
Figure 4Histopathological findings in primary malignant hypertension related kidney injury (40×).
Endothelial injury and thrombogenesis precedes myointimal swelling and proliferation, leading to vascular lumina narrowing or obliteration.
Figure 5Histopathological findings in primary malignant hypertension related kidney injury (40×).
(A) Mild lesion; (B) Moderate lesion; and (C) Marked lesion.
Frequency of CD4+CD25+ cells (%) and clinical parameters in patients.
| Index | r | |
|---|---|---|
| SBP | −0.236 | n.s. |
| DBP | −0.310 | n.s. |
| BUN | −0.524 | <0.05 |
| SUA | −0.538 | <0.01 |
| eGFR | 0.867 | <0.01 |
| 24 h UP | −0.583 | <0.01 |
| Hematuria | −0.206 | n.s. |
| Serum C3 | 0.233 | n.s. |
| Serum IL-2 | −0.124 | n.s. |
| Supernatant IL-4 | −0.746 | <0.01 |
| Serum IL-6 | −0.228 | n.s. |
| vWF (%) | −0.231 | n.s. |
| VCAM (ng/mL) | −0.185 | n.s. |
n.s., not significant; SBP, systolic blood pressure; DBP, diastolic blood pressure; Scr, serum creatinine; SUA, serum uric acid; eGFR, estimated glomerular filtration rate; 24-h UP, 24- hours urinary protein. vWF, von Willebrand factor; VCAM, vascular cell adhesion molecule.
Figure 6The number of CD4+CD25+ cells and severity of disease.
The number of CD4+CD25+ cells in primary MHTN related kidney injury tended to decrease in parallel with the severity of the lesion increased, although the difference was not significant.